In the RIACE trial [44], 15,773 individuals with type 2 diabetes were enrolled and classified based on albuminuria and eGFR in four groups: no DKD (Alb−/eGFR−), albuminuria alone (Alb+/eGFR−), reduced eGFR alone (Alb−/eGFR+), or both albuminuria and reduced eGFR (Alb+/eGFR+). This evidence concerns the gene ALB and diabetic kidney disease.